Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia

Karaboga B., ÇİLLİ A.

TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, cilt.63, sa.2, ss.94-101, 2015 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 63 Sayı: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.5578/tt.9110
  • Dergi Adı: TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.94-101
  • Anahtar Kelimeler: Community acquired pneumonia, ampicilline-sulbactam, fluoroquinolone
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Introduction: For hospitalized patients, monotherapy with a respiratory Fluoroquinolone (F) and dual therapy combination a ampicilline-sulbactam + a macrolide (AS+ M) are extensively used in the treatment of community-acquiredpneumonia (CAP). In this study, empirical AS + M combination therapy versus F monotherapy was compared in hospitalized adult CAP patients.